Roche’s decision to end development of tominersen in Huntington’s disease is sharpening the competitive read-through for Wave Life Sciences’ allele-selective antisense oligonucleotide strategy. Analysts at Rodman & Renshaw pointed to the tominersen Phase 2 failure as a mechanism-level signal: they attributed the lack of clinical benefit to sustained non-selective knockdown, despite reductions in mutant huntingtin and neurofilament light chain. Roche had partnered with Ionis on tominersen, a non-selective antisense approach. Wave’s WVE-003, by contrast, is designed to degrade mHTT mRNA while preserving wild-type huntingtin protein by targeting a polymorphism unique to the mutant allele. Wave’s asset sits near a Phase 2/3 registrational trial, and analysts said Roche’s withdrawal “tightens” the case that allele selectivity and wtHTT-sparing could matter for future efficacy in HD.